Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the use of finasteride for treating benign prostatic hyperplasia and its chemopreventive potential for prostate cancer, but it calls for further discussion on its preventive use in high-risk groups.

In this study, researchers found no significant difference in bladder cancer incidence between men treated with finasteride and those given a placebo, suggesting that reduced dihydrotestosterone levels may not impact bladder cancer risk.

This review discusses various targets for treating prostate cancer and benign prostatic hyperplasia and reports on recent studies of new compounds and 5α-reductase inhibitors, but provides no new experimental results.

This review discusses medical treatments for lower urinary tract symptoms suggestive of benign prostatic hyperplasia, focusing on their effects, side-effects, and implications for treatment goals, but reports no new clinical results.

This meta-analysis found that male pattern baldness is associated with an increased risk of aggressive prostate cancer and benign prostatic hyperplasia.

This study found that patients with androgenetic alopecia had a higher incidence of metabolic syndrome and benign prostatic hyperplasia compared to those without the condition.

This review discusses medical therapies for benign prostatic hyperplasia, highlighting the importance of personalizing treatments to individual patient needs and preferences.

Saw palmetto helps with nighttime urination and urine flow, similar to finasteride.

This review concludes that global literature supports the lipidosterolic extract of Serenoa repens as efficacious and safe for treating lower urinary tract symptoms, with some studies showing equivalence to common pharmacologic agents.

This study suggests that male pattern baldness—especially moderate to severe—is an independent risk factor for prostate cancer and high-grade disease in men undergoing prostate biopsy.

This review discusses methods for improving study design and evaluation in sexual health literature and reports no new clinical results; it highlights current methodological issues and the benefits of validated questionnaires.

Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.

The authors concluded that dutasteride is effective and generally safe for managing benign prostatic hyperplasia and may reduce prostate cancer risk.

This literature review identified that phosphodiesterase 5 inhibitors, such as Tadalafil, are highly effective in improving lower urinary tract symptoms associated with benign prostatic hyperplasia, while the efficacy of saw palmetto remains inconsistent.

This study found that in men with benign prostatic hyperplasia, 5-alpha reductase inhibitors significantly increased the risk of gynecomastia and breast tenderness compared to placebo or alpha-blockers.

In this study, androgenetic alopecia patients with thin hair were found to have a higher likelihood of experiencing prostatic enlargement and related urinary symptoms compared to those with thicker hair.

This protocol outlines a planned Cochrane Review to evaluate the effects of 5-alpha-reductase inhibitors on lower urinary tract symptoms caused by benign prostatic obstruction, and it reports no new findings.

This study discusses the role of 5α-reductase inhibitors in managing lower urinary tract symptoms caused by benign prostatic hyperplasia and suggests their potential use in other conditions like prostate cancer chemoprevention and androgenetic alopecia treatment, emphasizing appropriate dosing to reduce surgical complications.

This review examines recent advancements in analytical techniques used to quantify dutasteride, a medication for enlarged prostate, in various biological samples and its commercial forms, emphasizing methods such as HPTLC, GC-MS, and HPLC.

This review explores the risk factors, associated comorbidities, and psychological impacts of early-onset androgenetic alopecia, highlighting its complexity and potential implications for treatment response and overall health.

The authors discuss BPH treatment options and highlight that while medications can manage symptoms, recent minimally invasive procedures may offer promise for elderly males who are not surgical candidates or wish to avoid surgery.

This article reviews the management of lower urinary tract symptoms, highlighting drug therapy advancements that have reduced the frequency of surgical interventions.

Using mirabegron and solifenacin together is safe and more effective for treating overactive bladder than using either drug alone.

The authors concluded that preoperative treatment with finasteride for a month effectively reduced perioperative bleeding and shortened hospital stays in patients undergoing transurethral resection of the prostate.

This abstract outlines a study evaluating dutasteride's effect on perioperative bleeding during transurethral resection of the prostate, but does not report any new clinical results.

This study found that ureteroileal anastomosis with direct intraluminal visualization had a 4.2% stricture rate, which compares favorably to other techniques with rates between 3.5% and 11.1%.

This study found that nonobese women with idiopathic hirsutism had significantly lower nitrite/nitrate concentrations and higher fibrinogen levels compared to controls, but similar levels to women with PCOS.

This study found that nonobese women with idiopathic hirsutism had higher fibrinogen levels and lower nitrite/nitrate concentrations compared to controls, similar to those with PCOS.

This study found that nonobese women with idiopathic hirsutism exhibited lower nitrite/nitrate concentrations and higher fibrinogen levels compared to control subjects, but these were similar to levels in women with polycystic ovary syndrome.

This study evaluated the persistent adverse effects of 5α-reductase inhibitors in men previously treated for androgenic alopecia and highlighted issues with sexual, genitourinary, physical, psychiatric, cognitive, and androgenic health.